Serial #97232109
LIVE

Serial Number

97232109

Owner

MediLink Therapeutics(Suzhou)Co.,Ltd.

Attorney

Timothy T. Wang

First Use Date

Jun 9, 2022

Filing Date

Jan 21, 2022

Add to watchlist:

No watchlists yet
View on USPTO

Serial #97232109 Trademark

Serial Number: 97232109 • Registration: 7634285

Serial #97232109 is a trademark filed by MediLink Therapeutics(Suzhou)Co.,Ltd. on January 21, 2022. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

MediLink Therapeutics(Suzhou)Co.,Ltd. (12 trademarks)

101 N. BLK B3, Biology Industrial Park
Suzhou, Jiangsu 215000 , CN

Entity Type: 99

Trademark Details

Filing Date

January 21, 2022

Registration Date

December 31, 2024

First Use Anywhere

June 9, 2022

First Use in Commerce

June 9, 2022

Published for Opposition

February 20, 2024

Goods & Services

Vaccines; Anti-cancer preparations; Biological preparations for the treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Chemical preparations for pharmaceutical or medical purposes, namely, for treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Cytostatics for pharmaceutical purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic preparations for medical purposes for detecting the presence of malignant, inflammatory and autoimmune disorders and conditions and tissue trauma in humans; Diagnostic reagents for medicinal use; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of antibody-drug conjugate that facilitate the delivery of pharmaceutical preparations; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicinal preparations for anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations, namely, elixirs for the treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Therapeutic pharmaceutical for the treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Tumor suppressing agents

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Dec 31, 2024 NRCC
REGISTERED-PRINCIPAL REGISTER
Dec 31, 2024 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Dec 9, 2024 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Dec 9, 2024 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Dec 7, 2024 SUPC
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Dec 7, 2024 AITU
USE AMENDMENT FILED
Sep 26, 2024 IUAF
TEAS STATEMENT OF USE RECEIVED
Sep 26, 2024 EISU
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Apr 16, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 4, 2024 NPUB
PUBLISHED FOR OPPOSITION
Feb 20, 2024 PUBO
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 31, 2024 NPUB
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 31, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 12, 2024 CNSA
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jan 3, 2024 RCCK
ASSIGNED TO EXAMINER
Nov 8, 2023 DOCK
ASSIGNED TO EXAMINER
Nov 7, 2023 DOCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
May 1, 2023 RCSC
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 31, 2022 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 31, 2022 GNSL
SUSPENSION LETTER WRITTEN
Oct 31, 2022 CNSL
ASSIGNED TO EXAMINER
Oct 28, 2022 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jan 27, 2022 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 26, 2022 NWOS
NEW APPLICATION ENTERED
Jan 25, 2022 NWAP